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Background: Children represent 10-20% of all systemic lupus erythematosus (SLE) patients. Their clinical
manifestations and outcomes vary with age. We aim to clarify the relationship between pubescent status and the
clinical manifestations of pediatric SLE.
Methods: In this study, pediatric SLE patients were divided into three groups, based on age at disease onset (≦8,
8–13 & 13–18 years), defined as prepubescent, pubescent and postpubescent, respectively. Initial clinical
manifestations and laboratory characteristics at diagnosis were analyzed.
Results: Ninety-six patients were entered into the study: 8 had disease onset before age 8, while 49 were between
8–13 and 39 of them were 13–18. Female predominance was noted in all three groups (2.5-7.0:1). Postpubescents
showed significantly more renal involvement and lymphopenia, along with lower levels of C3 and C4, when
compared with prepubescents. They also showed significantly more lymphopenia when compared with
pubescents. Pubescents showed significantly more renal involvement, leukopenia and lupus anticoagulant (LAC)
positivity, along with lower C3 and C4 levels, when compared with prepubescents. Pubescents also showed
significantly higher anti-Sm antibody positivity when compared with postpubescents. Prepubescents showed
significantly more splenomegaly and anti-Jo-1 antibody positivity when compared with those of pubescents. The
results showed that the disease activity (SLEDAI-2K score) correlated positively with age at disease onset and
negatively with disease duration before diagnosis (p= 0.011).
Conclusions: Age at disease onset is related to initial manifestations in pediatric SLE patients at our center. Certain
parameters such as renal involvement, splenomegaly, low C3 level, low C4 level, lymphopenia, leukopenia, and anti-
Sm & anti-Jo-1 antibody were found to be significantly different among the age groups. Renal involvement might
be the key symptom that varies with age.
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Systemic lupus erythematosus (SLE) predominantly affects
young women who are at a reproductive age. SLE com-
mences in childhood in 10-20% of patients and early-onset
SLE before age of five is rare [1-7]. Most childhood studies
have largely omitted patients younger than 10 years old [8-
12]. Genes, environment, neuroendocrinology, female sex
hormone levels and immune dysregulation might contrib-
ute to SLE development [13-17].
Clinical manifestations in SLE patients are extremely
variable and its course is unpredictable. The clinical
course can range from mild to severe and can be poten-
tially life-threatening. SLE that begins at childhood tends
to be more severe, with frequent cardiac, pulmonary and
renal involvement and is associated with a more aggres-
sive course than those with older age [18]. Common
manifestations are nephritis, hematological involvement
including anemia, thrombocytopenia, arthritis, central
nervous system lupus, and skin involvement. The relative
incidence of these manifestations are different in adults
and different age groups of children [19]. The correlation
between gender, ethnicity, pubescent status, or age at
disease onset and the manifestations and outcomes in
children with SLE is well delineated [18-20].
The purpose of this study is to investigate the correla-
tions between pubescent status, age at disease onset, and
the manifestations and outcomes of pediatric SLE. We
compared the initial clinical manifestations and labora-
tory findings of pediatric SLE patients in prepubescent,
pubescent and postpubescent groups to determine
whether or not pubescent status correlates with the
above variables and outcomes.
Methods
Study design and patient selection
Patients from the Department of Pediatrics, National
Taiwan University Hospital, who met the criteria for SLE,
from 1975–2010, were reviewed. SLE criteria were utilized
in accordance with the American College of Rheumatology
(ACR) 1997 revisions [21,22].
Patients were divided into three groups, based on age at
disease onset. Group A included patients ≦8 years old (pre-
pubescent), while group B patients were 8–13 (pubescent)
and group C patients were 13–18 (postpubescent) [23,24].
Initial clinical manifestations and laboratory findings were
recorded during diagnosis.
Data collection
Age, sex, disease duration before diagnosis, initial clinical
presentation, laboratory findings, family (1st & 2nd degree
relatives) autoimmune history and Systemic Lupus
Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
scores upon diagnosis were all noted [25]. The definition
of disease onset is the onset of disease symptomsrelated to SLE criteria. The disease duration before
diagnosis is the period from when symptoms first began
to the time the child met ACR criteria for SLE.
Mucocutaneous system involvement included malar
rash, discoid rash, oral ulcer, photosensitivity and alope-
cia. Musculoskeletal system involvement included myal-
gia that resolved with steroid therapy, autoimmune
myositis proven by muscle biopsy, and arthritis. Arthritis
was defined as the involvement of two or more joints,
characterized by tenderness and swelling. Reticuloen-
dothelial system involvement included splenomegaly,
lymphadenopathy, hepatomegaly and autoimmune hepa-
titis, proven by liver biopsy. Gastrointestinal system in-
volvement entailed severe abdominal pain that resolved
with steroid therapy. Renal involvement included the
presence of proteinuria (>0.5 g/day or 3-plus in urine
examination or cellular casts). The renal biopsy was clas-
sified by World Health Organization (WHO) criteria (six
categories) [26]. Central nervous system involvement
included seizure, psychosis and vasculitis, identified by
imaging. Serositis included pleural effusion, pericardial
effusion, ascites, and peritonitis.
Laboratory thresholds for SLE included leukopenia
(<4000/mm3), lymphopenia (<1500/mm3) and thrombo-
cytopenia (<100,000/mm3). Complement fractions, C3 and
C4, were considered abnormal if they were below two stand-
ard deviations. Antinuclear antibody (ANA) titer and anti-
double stranded DNA (anti-dsDNA) antibody level were
considered positive when the former was >1:160 and the lat-
ter was >75 IU/ml, as determined by enzyme immunoassay
(EIA). Anti-cardiolipin antibodies (aCLs) and anti- extract-
able nuclear antigens (anti-ENAs) were assayed by enzyme-
linked immunosorbent assay (ELISA). Lupus anti-coagulant
(LAC) was detected through activated partial thromboplastin
time, the kaolin clotting time, and the dilute Russell’s viper
venom time. We also used Systemic Lupus Erythematosus
Disease Activity Index 2000 (SLEDAI-2K) scores as a meas-
ure of disease activity at diagnosis.
Outcomes
Mortality was defined as death. All survivors were fol-
lowed-up from disease onset until May 2010. Morbidity
as renal disease requiring dialysis and renal transplant
were also recorded.
Statistical analysis
Descriptive statistics were used for initial clinical mani-
festations and laboratory data. We used Pearson’s Chi-
squared test to compare categorical variables between
the three groups and Mann–Whitney U-testing or Krus-
kal Wallis test for continuous variables. Spearman’s cor-
relation coefficients were used to calculate the
correlation between disease duration before diagnosis
and disease activity at diagnosis. Kaplan-Meier survival
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were considered significant for p-values< 0.05.
Results
Patients
Initial clinical manifestations and laboratory findings are
summarized in Table 1. Out of 96 total patients, 74 were
female (77.1%). Prepubescents (group A) included 8
patients, while there were 49 pubescents (group B) and 39
postpubescents (group C). The female-to-male (F:M) ratio
was 7:1 in group A, 2.5:1 in group B and 4.6:1 in group C.
There was no significant difference in female prevalence
among the three groups.
All patients were ethnic Chinese. A family history of
autoimmune disease was noted in 12.5% of prepubes-
cents, 14.3% of pubescents and 18% of postpubescents.
Mean age at disease onset was 6.8 years (range: 4.7-7.9)
in group A, 11 (8.8 -12.9) in group B and 14.6 (13–17.9)
in group C.
Disease duration before diagnosis was defined as the
time interval between disease onset and diagnosis. Mean
values were 21.3 months (range: 0.8-90) for group A,
9.2 months (0.1-96) for group B and 4.4 months (0.3-24)
for group C. In prepubescents, mean disease duration
before diagnosis was 2.3-4.8 times longer than values
seen for groups B and C (Figure 1).
Initial clinical manifestations
There was no significant difference in mucocutaneous,
musculoskeletal, reticuloendothelial (lymphadenopathy,
hepatosplenomegaly and autoimmune hepatitis), gastro-
intestinal, and central nervous system involvement among
the three groups. More than half of the patients had
mucocutaneous, musculoskeletal and hematological in-
volvement in each group (Table 1). Gastrointestinal and
central nervous system involvement were not common in
each group (Table 1).
Renal involvement was present at diagnosis in 23
group C patients (59%) and its frequency significantly
increased with age (12.5% in group A, 49% in group B)
(p= 0.009, A vs. B; p= 0.002, A vs. C) (Table 2). Twenty
patients underwent renal biopsy; class IV lupus nephritis
was the most common in groups B (75%) and C (62.5%).
Six patients (30%) had mixed lupus nephritis. One group
C patient presented with mixed Class II and V lupus
nephritis. Three patients had mixed Class III and IV and
two had mixed Class IV and V lupus nephritis in group
B. We used the same criteria for deciding whether to
perform a renal biopsy: 1) When patients met protein
excretion greater than 500 mg/day; or 2) Had an active
urinary sediment with hematuria (five or more red blood
cells per high power field, most of which are dys-
morphic) and often pyuria and cellular casts. Due to the
conservative attitude and culture of Chinese patients,some patients rejected the renal biopsy and sometimes
the patient’s condition itself did not allow renal biopsy.
Neurological involvements were noted in three group
B patients; manifestations included seizure and psych-
osis. One patient in group C had a seizure. Although
neurological involvement seemed more frequent in
group B, the difference among all three groups did not
reach statistical significance. Splenomegaly was signifi-
cantly more common in group A than B (p= 0.013)
(Table 2).
Manifestations that became more frequent with age
included renal involvement, serositis, alopecia, and
hematological involvement. Differences in renal involve-
ment among the three groups were also significant
(p= 0.01) (Table 1).
Cumulative disease activity at diagnosis was measured
using the SLEDAI score. The mean score was 10.6
(range: 2–20) in group A, 13.8 (4–30) in group B and
14.7 (4–28) in group C. Mean SLEDAI score increased
with age, though the differences were not significant
(Figure 2).
Laboratory data
Lymphopenia was present at diagnosis in 25 group C
patients (64.1%); its frequency increased with age (12.5%
in group A, 36.7% in group B). Group C had a significantly
higher prevalence of lymphopenia than the other two
groups. (p=0.011 for B vs. C, p=0.007 for A vs. C)
(Table 2). Low C3 levels were noted at diagnosis in 34
group C patients (87.2%) and their frequency also
increased with age (37.5% in group A, 83.7% in group B).
Groups B and C showed significantly higher prevalence of
low C3 levels when compared to group A (p=0.004 for A
vs. B, p=0.002 for A vs. C). C4 levels showed a similar
prevalence (Table 2); groups B and C also showed signifi-
cantly higher prevalence of low C4 levels when compared
with group A (p=0.018 for A vs. B, p=0.015 for A vs. C).
Group B anti-Sm antibody positivity (33%) was signifi-
cantly more prevalent when compared with group C (0%)
(p=0.001) while anti-Jo-1 antibody positivity was signifi-
cantly more prevalent in group A (16.7%) when compared
with group B (0%) (p=0.039) (Table 2). Leukopenia and
LAC positivity were significantly more prevalent in group
B than group A (p=0.047 & p=0.044, respectively). Group
A had a significantly higher prevalence of splenomegaly
when compared to group B (p=0.013) (Table 2). No statis-
tical differences were found in ANA titer, anti-dsDNA
antibody level and aCL positivity. Low levels of C3, C4 and
high level of anti-dsDNA antibodies correlated with higher
disease activity. Compared with the mean level of C3, C4
and anti-dsDNA antibody of each group, we also found
that the disease activity increased with age (Figure 1 A-C).
This result was compatible with the increasing mean SLE-
DAI score of each group (Figure 2).
Table 1 Initial clinical manifestations and laboratory characteristics of pediatric SLE patients of different pubescent age
groups
Characteristics Group A(n= 8) Group B (n = 49) Group C (n =39) Significance
Mean onset age: years (range) 6.8 (4.7-7.9) 11(8.8-12.9) 14.6(13–17.9)
Gender (F:M) 7:1 2.5:1 4.6:1 ns
Positive family history (%) 1(12.5) 7 (14.3) 7 (18) ns
Mean disease duration before
diagnosis: months (range)
21.3 (0.8-90) 9.2 (0.1-96) 4.4 (0.3-24) ns
Organ involvement (%)
Mucocutaneous 6 (75) 35 (71.4) 29 (74.4) ns
Malar rash 5 (62.5) 26 (53.1) 19 (48.7) ns
Discoid rash 1 (12.5) 3 (6.1) 2 (5.1) ns
Oral ulcer 4 (50) 19 (38.8) 12 (30.8) ns
Photosensitivity 2 (25) 6 (12.2) 3 (7.7) ns
Alopecia 0 (0) 7 (14.3) 7 (18) ns
Musculoskeletal 5 (62.5) 26 (53.1) 21 (53.9) ns
Myalgia 1 (12.5) 3 (6.1) 4 (10.3) ns
Arthritis 4 (50) 24 (49) 19 (48.7) ns
Reticuloendothelial system 3 (37.5) 6 (12.2) 6 (15.4) ns
Lymphadenopathy 2 (25) 4 (8.2) 3 (7.7) ns
Splenomegaly 1 (12.5) 0 (0) 2 (5.1) ns
Hepatic 1 (12.5) 2 (4.1) 1 (2.6) ns
Gastrointestinal 1 (12.5) 2 (4.1) 3 (7.7) ns
Renal 1 (12.5) 24 (49) 23 (59) p= 0.01
WHO class I 0/0 (0) 0/12 (0) 0/8 (0) ns
WHO class II 0/0 (0) 1/12 (8.3) 2/8 (25) ns
WHO class III 0/0 (0) 4/12 (33.3) 0/8 (0) ns
WHO class IV 0/0 (0) 9/12 (75) 5/8 (62.5) ns
WHO class V 0/0 (0) 4/12 (33.3) 1/8 (12.5) ns
WHO class VI 0/0 (0) 0/12 (0) 1/8 (12.5) ns
Central nervous system 0 (0) 3 (6.1) 1 (2.6) ns
Serositis 0 (0) 5 (10.2) 9 (23.1) ns
Pleural effusion 0 (0) 4 (8,2) 6 (15.4) ns
Pericardial effusion 0 (0) 2 (4.1) 5 (12.8) ns
Ascites/Peritonitis 0 (0) 2 (4.1) 4 (10.3) ns
Hematologic 6 (75) 38 (77.6) 34 (87.2) ns
Anemia 6 (75) 34 (69.4) 30 (76.9) ns
Leukopenia 0 (0) 17 (34.7) 13 (33.3) ns
Lymphopenia 1 (12.5) 18 (36.7) 25 (64.1) p= 0.005
Thrombocytopenia 1 (12.5) 9 (18.4) 12 (30.8) ns
Laboratory (%)
Low C3 3 (37.5) 41 (83.7) 34 (87.2) p= 0.004
Low C4 3 (37.5) 42 (85.7) 34 (87.2) p= 0.03
Autoantibodies positive :number (%)
ANA 8 (100) 46 (93.9) 36 (92.3) ns
Anti-dsDNA antibody 5 (62.5) 44 (89.8) 30 (76.9) ns
aCL 0/2 (0) 4/12 (33.3) 3/18 (16.7) ns
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Table 1 Initial clinical manifestations and laboratory characteristics of pediatric SLE patients of different pubescent age
groups (Continued)
LAC 0/2 (0) 1/13 (7.7) 1/18 (5.6) ns
Anti-ENA
Anti-RNP 3/6 (50) 10/30 (33.3) 4/29 (13.8) ns
Anti-Jo-1 1/6 (16.7) 0/30 (0) 0/29 (0) p= 0.012
Anti-Scl-70 0/6 (0) 3/30 (10) 1/29 (3.4) ns
Anti-Ro 4/6 (66.6) 10/30 (33.3) 11/29 (37.9) ns
Anti-La 2/6 (33.3) 4/30 (13.3) 3/29(10.3) ns
Anti-Sm 1/6 (16.7) 10/30 (33.3) 0/29 (0) p= 0.009
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All surviving patients were followed-up from disease
onset until May 2010. Mortality was defined as death.
Mean follow-up was 9.7 years (range: 2.4-35.0) in group
A, 8.3 (0.1-26.0) in group B and 7.5 (0.5-30.8) in group
C. The survival rate was 100% in group A, 88.3% in
group B and 97.4% in group C (Figure 3). Two patients
died in group B; causes of death were combined renalFigure 1 Levels of C3, C4 & anti-dsDNA antibody, and disease duratio
anti-dsDNA antibody, and disease duration before diagnosis, for pediatric S
Mean C3 level was 72 mg/dl in group A, 48 mg/dl in group B and 50 mg/d
group B and 8.2 mg/dl in group C. (C) Mean anti-dsDNA antibody level wa
C. (D) Mean disease duration before diagnosis was 21.3 months in group Afailure, respiratory failure and pneumonia in one patient
while the other had a severe respiratory syncytial virus
infection. One patient died in group C due to severe
serositis and renal failure. Seven patients were lost to fol-
low-up over one year in group C and five patients in
group B. With regards to morbidity, eight (16.3%)
patients required dialysis in group B and four (10.2%) in
group C. Three of the eights patients requiring dialysisn before diagnosis, for pediatric SLE patients. Levels of C3, C4 &
LE patients at prepubescent, pubescent and postpubescent ages. (A)
l in group C. (B) Mean C4 level was 13 mg/dl in group A, 8.6 mg/dl in
s 145 IU/ml in group A, 295 IU/ml in group B and 349 IU/ml in group
, 9.2 months in group B, and 4.4 months in group C.
Table 2 Differential manifestations in prepubescent,
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nificant differences noted among the three groups in
these mortality and morbidity findings.
Discussion
Early-onset SLE before the age of five is rare [3]; simi-
larly this early onset occurred in only one of our patients
(4.7 years old) while eight (8.3%) had onset before theFigure 2 Mean SLEDAI score at diagnosis for pediatric SLE
patients. Mean SLEDAI score at diagnosis for pediatric SLE patients
at prepubescent, pubescent and postpubescent ages. Mean score
was 10.6 in group A, 13.8 in group B and 14.7 in group C.age of eight. In childhood, girls are affected 4.5 times
more often than boys, although the overall ratio varies
with age at onset [27-31]. A previous study showed the
female predominance is not striking before puberty [20].
The significant role played by sex hormone in the female
preponderance was more often noted in postpubescents
than prepubescents [18]. The same study also suggested
that the greater prevalence of family autoimmune history
seen with patients under the age of two years stems from
genetic predisposition [18]. However, in the present
study, the female-to-male (F:M) ratio was 7:1 in prepu-
bescents, 2.5:1 in pubescents and 4.6:1 in postpubes-
cents. Prepubescents were 1.5-2.8 times more likely to be
female than postpubescent and pubescents. The highest
frequency of positive family history was seen in the post-
pubescent group (18%), while in prepubescents and pub-
escents were 12.5% and 14.3%, respectively. These
differences may be affected by many factors, including
study method, ethnic diversity, pubescent status and dif-
ferent age cutoff values of the patients compared with
the previous studies [18-20].
Age at onset for pediatric SLE patients is related to the
expression of the disease in terms of initial clinical mani-
festations, serological findings, and disease activity [32-
35]. We found no significant difference in the incidence
of mucocutaneous, musculoskeletal, reticuloendothelial
(lymph nodes, hepatosplenomegaly and autoimmune
hepatitis) and central nervous system involvement. In
contrast, renal involvement was more prevalent in pub-
escents and postpubescents than prepubescents; indeed,
this may be the key symptom that varies with age. The
incidence of lymphopenia also increased with age, while
the incidence of low C3 and C4 levels increased gener-
ally. Marked lymphopenia is significantly related to
complement decrease [36]. Hypocomplementemia and
positivity for anti-dsDNA antibody, besides being helpful
as diagnostic aides, associated more with presence of
renal involvement, though the correlation was not statis-
tically significant [19]. In our study, hypocomplemente-
mia significantly correlated with the renal involvement
(p= 0.017 C3/0.031 C3 or C4). We found that the trend
of incidence of renal involvement, lymphopenia, low C3
and C4 level were similar. However, the real mechanisms
remain unclear.
It has been shown that changes in the levels of sex hor-
mones led to a number of changes in both innate and
adaptive immune cells, affecting antigen presentation,
numbers of T and B cells, and antibody secretion [37]. In
our study, anti-Sm antibody positivity was significantly
greater in pubescents than that of postpubescents. Anti-
Jo-1 antibody positivity was significantly greater in prepu-
bescents compared to that of pubescents. LAC positivity
was significantly more prevalent in pubescents than pre-
pubescents. According to our results, we suggest that
Figure 3 Kaplan-Meier analysis for survival rates of pediatric
SLE patients. Kaplan-Meier analysis for survival rates of pediatric SLE
patients at prepubescent, pubescent and postpubescent ages. Survival
rate was 100% in group A, 88.3% in group B and 97.4% in group C.
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antibody in three groups. However, more studies are
needed to clarify the role of sex hormones in the gener-
ation of these autoantibodies.
The correlation of pubescent status and age at disease
onset on the disease activity and the outcome in children
with SLE is controversial [38]. Early onset disease has
been suggested to have higher disease activity and mor-
tality [18-20]. Our results demonstrated that mean SLE-
DAI score at onset of SLE was higher with increased age
of onset. The mean SLEDAI score was compatible with
mean C3, C4 levels and anti-dsDNA antibody levels of
each group (Figures 2, 1 A-C). Mean disease duration
before diagnosis was shorter with decreased age of onset;
the higher activity of the disease, the shorter the duration
before diagnosis (Figures 2, 1 D). Disease activity posi-
tively correlates with age at disease onset and negatively
correlates with disease duration before diagnosis
(p= 0.011) (data not shown). The survival rate was 100%
in prepubescents, 88.3% in pubescents and 97.4% in
postpubescents (Figure 3). These effects might be due to
the greater prevalence of some major organs involve-
ment such as renal, hematological involvement, and
serositis, along with higher activity causing the survival
rate to decrease with pubescents and postpubescents.
Renal failure, respiratory failure, infection and serositis
contributed to the major causes of death in our patients.
Two-third of patients that expired had received alterna-
tive treatment such as herbal medications and qigong
and had stopped taking their original medications for six
months. The outcome of SLE is dependent on early diag-
nosis and treatment, and, most importantly, patients’
willingness to accept the diagnosis and the need toadhere to advice about therapy [39]. Thus, poor adher-
ence may contribute to the poor outcome in our
patients. Sometimes ethnicity is a challenge in the treat-
ment of our patients, because patients of Asian origin
are generally quite concerned about the side effects of
medicines used for the treatment of SLE. They also felt
that medicines in general were harmful and overused,
believing that traditional or other non-medical treat-
ments could be quite effective. Communication and edu-
cation are also important issues that may affect the
outcome in our patients.
Several studies have reported that children and adoles-
cents often have an aggressive and severe clinical course
and more frequent renal involvement as compared
to adults. In our study, we made it clear that the preva-
lence of renal involvement were significantly different
in subgroups of children. The pubescents and postpubes-
cents showed significantly higher prevalence of renal in-
volvement along with higher disease activity than
prepubescents. Eight (16.3%) patients required dialysis in
pubescents and four (10.2%) in postpubescents. The per-
centage of renal dialysis is high in pubescents and post-
pubescents and another study showed about 6.5% of the
patients over age 5 requiring renal dialysis [19].
With regards to the limitations of our study, the first
was that there was missing data in our retrospective
study. Patients who almost met but failed to meet the
criteria of SLE had to be excluded from our study. As a
result, this had an impact on the number of patients
entered into our study and the results. In addition, there
were only eight patients in the prepubescent group; more
patients might be needed to make statistical analysis
more reliable. Another limitation was that we did not
have access to detailed information about the SLE treat-
ment of patients which has certainly changed with time.
Treatment changes may have affected the mortality rate.
Further, the sex hormone profile and the age of menar-
che were not recorded, so we could not fully clarify the
role of sex hormone. The Tanner stage of each patient
was also not recorded to evaluate the physical status of
puberty. All patients were from an ethnic Chinese popu-
lation and implications for other ethnic groups is not
clear. As the definition of disease onset was from when
symptoms related to SLE criteria first began so, this
introduces some bias. This self-reporting bias of the tim-
ing of disease onset existed and it also likely affected the
disease duration before diagnosis.
Conclusions
In our population of SLE children and adolescents in
Taiwan, age at disease onset is related to initial manifes-
tations in pediatric SLE patients. Certain parameters
such as renal involvement, splenomegaly, low C3 level,
low C4 level, lymphopenia, leukopenia, and anti-Sm &
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ent among the age groups, while SLEDAI score at onset
of SLE was higher with increased age of onset. Renal in-
volvement occurred in approximately 50% of our
patients over the age of eight and 10-16% of them
needed dialysis in their life. Renal involvement is critical
and needs close monitoring. As seen in other popula-
tions, adherence to medications played a critical role in
the survival rate of our SLE patients.
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